Search CommunityWalk:


BioSciCon, Inc

14905 Forest Landing Circle
Rockville, MD, USA

Category: Diagnostic/Imaging

Used in the following map:

Maryland Biotech Industry Map

BioSciCon, Inc is a biotech company focused on the development of a proprietary platform MarkPap® technology for improving Pap test and a more accurate early detection of cervical cancer and precancerosis. It was incorporated in 1996 with a mission to bring the new MarkPap® Technology products to public benefit and save women's lives around the world.

BioSciCon is a R&D component of a consortium with three more companies: MarkPap LLC, MarkPap Pacific LLC and The Global Academy for Women's Health, Inc. It designs and develops patented Pap test related products and services under the brand name MarkPap®. The company sponsors the development of MarkPap® System, a proprietary biomarker-based technology with potentials for development of multiple medical devices for in vitro diagnostics of women's health status. The MarkPap® System is an assembly of invitro diagnostic devices and procedures that may have practical application in cervical cancer screening for the improvement of Pap test. It is also a research tool to study cervical acid phosphatase in relation to the development of cervical pre-cancerous lesions and their transformation into cancer. In addition, MarkPap test could be used for determination of acid phosphatase in other epithelial tumors (oral, breast, lung, laryngeal, thyroid, colon, prostate) where this enzyme has been related to the tumor biology and has been considered as a target for new chemotherapies.

BioSciCon's MarkPap® products and laboratory services available for commercialization are: MarkPap® Test (method, assay, procedure), MarkPap® Research Kit and MarkPap® Accessories: MarkPap® Solution. Its MarkPap® Cytopreservative Solution is an accessory to the MarkPap® Research Kit. The solution is made for the preservation of enzyme marker activity and cell morphology during an extended period of time. The company's MarkPap Digital concept allows evaluation of cytological specimens at distance (telecytopathology), using digital images sent from a remote laboratory sites.